These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 20691028

  • 1. Calcitriol (1,25-dihydroxycholecalciferol) enhances mast cell tumour chemotherapy and receptor tyrosine kinase inhibitor activity in vitro and has single-agent activity against spontaneously occurring canine mast cell tumours.
    Malone EK, Rassnick KM, Wakshlag JJ, Russell DS, Al-Sarraf R, Ruslander DM, Johnson CS, Trump DL.
    Vet Comp Oncol; 2010 Sep; 8(3):209-20. PubMed ID: 20691028
    [Abstract] [Full Text] [Related]

  • 2. Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor.
    Halsey CH, Gustafson DL, Rose BJ, Wolf-Ringwall A, Burnett RC, Duval DL, Avery AC, Thamm DH.
    BMC Vet Res; 2014 May 06; 10():105. PubMed ID: 24885200
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Evaluation of prognostic indicators in dogs with multiple, simultaneously occurring cutaneous mast cell tumours: 63 cases.
    O'Connell K, Thomson M.
    Vet Comp Oncol; 2013 Mar 06; 11(1):51-62. PubMed ID: 22235766
    [Abstract] [Full Text] [Related]

  • 7. Synergistic Effect of Toceranib and Nanohydroxyapatite as a Drug Delivery Platform-Physicochemical Properties and In Vitro Studies on Mastocytoma Cells.
    Sobierajska P, Serwotka-Suszczak A, Targonska S, Szymanski D, Marycz K, Wiglusz RJ.
    Int J Mol Sci; 2022 Feb 09; 23(4):. PubMed ID: 35216060
    [Abstract] [Full Text] [Related]

  • 8. Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study.
    Robat C, London C, Bunting L, McCartan L, Stingle N, Selting K, Kurzman I, Vail DM.
    Vet Comp Oncol; 2012 Sep 09; 10(3):174-83. PubMed ID: 22235914
    [Abstract] [Full Text] [Related]

  • 9. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs.
    Isotani M, Ishida N, Tominaga M, Tamura K, Yagihara H, Ochi S, Kato R, Kobayashi T, Fujita M, Fujino Y, Setoguchi A, Ono K, Washizu T, Bonkobara M.
    J Vet Intern Med; 2008 Sep 09; 22(4):985-8. PubMed ID: 18564222
    [Abstract] [Full Text] [Related]

  • 10. The tyrosine kinase inhibitor imatinib [STI571] induces regression of xenografted canine mast cell tumors in SCID mice.
    Kobie K, Kawabata M, Hioki K, Tanaka A, Matsuda H, Mori T, Maruo K.
    Res Vet Sci; 2007 Apr 09; 82(2):239-41. PubMed ID: 16919303
    [Abstract] [Full Text] [Related]

  • 11. Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs.
    Burton JH, Venable RO, Vail DM, Williams LE, Clifford CA, Axiak-Bechtel SM, Avery AC, Thamm DH.
    J Vet Intern Med; 2015 Apr 09; 29(4):1098-104. PubMed ID: 26119008
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Phosphorylated KIT as a predictor of outcome in canine mast cell tumours treated with toceranib phosphate or vinblastine.
    Thamm DH, Weishaar KM, Charles JB, Ehrhart EJ.
    Vet Comp Oncol; 2020 Jun 09; 18(2):169-175. PubMed ID: 31365175
    [Abstract] [Full Text] [Related]

  • 14. Susceptibility of the C2 canine mastocytoma cell line to the effects of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
    Elders RC, Baines SJ, Catchpole B.
    Vet Immunol Immunopathol; 2009 Jul 15; 130(1-2):11-6. PubMed ID: 19185923
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells.
    Gleixner KV, Rebuzzi L, Mayerhofer M, Gruze A, Hadzijusufovic E, Sonneck K, Vales A, Kneidinger M, Samorapoompichit P, Thaiwong T, Pickl WF, Yuzbasiyan-Gurkan V, Sillaber C, Willmann M, Valent P.
    Exp Hematol; 2007 Oct 15; 35(10):1510-21. PubMed ID: 17681669
    [Abstract] [Full Text] [Related]

  • 17. Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours.
    Smrkovski OA, Essick L, Rohrbach BW, Legendre AM.
    Vet Comp Oncol; 2015 Sep 15; 13(3):314-21. PubMed ID: 23845124
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.
    Potapova O, Laird AD, Nannini MA, Barone A, Li G, Moss KG, Cherrington JM, Mendel DB.
    Mol Cancer Ther; 2006 May 15; 5(5):1280-9. PubMed ID: 16731761
    [Abstract] [Full Text] [Related]

  • 20. An immunohistochemical study of vitamin D receptor expression in canine cutaneous mast cell tumours.
    Russell DS, Rassnick KM, Erb HN, Vaughan MM, McDonough SP.
    J Comp Pathol; 2010 May 15; 143(2-3):223-6. PubMed ID: 20334872
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.